Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Seth Gordhandas Sunderdas Medical College

Status and phase: Completed; Phase 3

Conditions: Cushing's Disease; Corticotroph Adenoma

Treatments: Drug: Cabergoline

Study type: Interventional

Funder types: Other

Identifiers

NCT00889525

EC/104/2005

Details and patient eligibility

About

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.

Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology

Exclusion criteria

• Patient's intolerance to drug or known sensitivity to ergot derivatives
• Pregnancy, lactation or female wishing to be pregnant
• Any serious medical illness
• Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Cabergoline

Experimental group

Treatment:

Drug: Cabergoline